The estimated Net Worth of Neal Walker is at least $8.67 Milion dollars as of 1 September 2024. Neal Walker owns over 9,466 units of Aclaris Therapeutics Inc stock worth over $1,611,430 and over the last 11 years he sold ACRS stock worth over $3,911,193. In addition, he makes $3,150,020 as President, Chief Executive Officer, Co-Founder a Director at Aclaris Therapeutics Inc.
Sign up
Neal Walker ACRS stock SEC Form 4 insiders trading
Neal has made over 30 trades of the Aclaris Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 9,466 units of ACRS stock worth $11,170 on 1 September 2024.
The largest trade he's ever made was exercising 156,679 units of Aclaris Therapeutics Inc stock on 1 March 2023 worth over $184,881. On average, Neal trades about 22,010 units every 70 days since 2014. As of 1 September 2024 he still owns at least 1,365,619 units of Aclaris Therapeutics Inc stock.
You can see the complete history of Neal Walker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Neal Walker biography
Dr. Neal Walker serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Dr. Walker co-founded our company and has served as President and Chief Executive Officer and a member of our Board since our inception in July 2012. Dr. Walker co-founded NeXeption, LLC in 2012 and NeXeption II, LLC in 2013. Between 2011 and 2012, Dr. Walker served as a consultant to a number of pharmaceutical companies. Dr. Walker co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy’s Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He began his pharmaceutical industry career at Johnson and Johnson, Inc. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private biotechnology companies. Dr. Walker received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine and a B.A. degree in Biology from Lehigh University. Dr. Walker’s experience as a board-certified dermatologist and the founder of our company and other pharmaceutical companies, his background in clinical and product development in dermatology and other fields, and his knowledge of the pharmaceutical industry contributed to the conclusion of our Board that he should serve as a director of our company.
What is the salary of Neal Walker?
As the President, Chief Executive Officer, Co-Founder a Director of Aclaris Therapeutics Inc, the total compensation of Neal Walker at Aclaris Therapeutics Inc is $3,150,020. There are no executives at Aclaris Therapeutics Inc getting paid more.
How old is Neal Walker?
Neal Walker is 50, he's been the President, Chief Executive Officer, Co-Founder a Director of Aclaris Therapeutics Inc since 2012. There are 13 older and 1 younger executives at Aclaris Therapeutics Inc. The oldest executive at Aclaris Therapeutics Inc is Maxine Gowen, 62, who is the Independent Director.
What's Neal Walker's mailing address?
Neal's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087.
Insiders trading at Aclaris Therapeutics Inc
Over the last 9 years, insiders at Aclaris Therapeutics Inc have traded over $101,608,525 worth of Aclaris Therapeutics Inc stock and bought 10,163,038 units worth $66,383,599 . The most active insiders traders include Braden Michael Leonard, Capital Management, Llc Kol... a Llc Fmr. On average, Aclaris Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $111,818. The most recent stock trade was executed by Kevin Balthaser on 1 September 2024, trading 1,000 units of ACRS stock currently worth $1,180.
What does Aclaris Therapeutics Inc do?
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
What does Aclaris Therapeutics Inc's logo look like?
Complete history of Neal Walker stock trades at Aclaris Therapeutics Inc a Aldeyra Therapeutics Inc
Aclaris Therapeutics Inc executives and stock owners
Aclaris Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Neal Walker,
President, Chief Executive Officer, Co-Founder, Director -
Kamil Ali-Jackson,
Co-Founder, Chief Compliance Officer, Secretary, Chief Legal Officer -
David Gordon,
Chief Medical Officer -
Frank Ruffo,
Co-Founder, Chief Financial Officer -
Dr. Neal S. Walker D.O.,
Co-Founder, CEO, Pres & Director -
Frank Ruffo,
Co-Founder, CFO & Treasurer -
Christopher Molineaux,
Independent Director -
Bryan Reasons,
Independent Director -
Andrew Powell,
Independent Director -
Anand Mehra,
Independent Director -
William Humphries,
Independent Director -
Andrew Schiff,
Independent Director -
Maxine Gowen,
Independent Director -
Vincent Milano,
Director -
James Loerop,
Chief Bus. Officer -
Dr. Paul S. Changelian Ph.D.,
Sr. VP of Biology -
Spencer Brown J.D.,
Sr. VP of Legal Affairs & Compliance Officer -
Dr. Joseph Monahan,
Chief Scientific Officer -
Rick Bierly,
Director -
Ventures Vii, Llc Vivo Vent...,
-
Stephen A. Tullman,
Director -
Albert Cha,
Director -
Stuart Shanler,
Chief Scientific Officer -
Capital Management, Llc Kol...,
-
Christopher Powala,
Chief Operating Officer -
Llc Fmr,
10% owner -
James E Deerfield Mgmt L.P....,
-
Capital Management Iii, Llc...,
-
Brett Fair,
Chief Commercial Officer -
Capital Management, Llc Kol...,
-
Venture Partners Viii, L.P....,
-
Gail Cawkwell,
Chief Medical Officer -
Joseph Monahan,
Chief Scientific Officer -
Douglas J. Manion,
Pres and CEO -
James Loerop,
Chief Business Officer -
Braden Michael Leonard,
-
Kevin Balthaser,
Chief Financial Officer